IL100458A - תכשירי רוקחות המכילים מתנגדים של קולטי קוויסקוואלייט - Google Patents

תכשירי רוקחות המכילים מתנגדים של קולטי קוויסקוואלייט

Info

Publication number
IL100458A
IL100458A IL10045891A IL10045891A IL100458A IL 100458 A IL100458 A IL 100458A IL 10045891 A IL10045891 A IL 10045891A IL 10045891 A IL10045891 A IL 10045891A IL 100458 A IL100458 A IL 100458A
Authority
IL
Israel
Prior art keywords
parkinson
pharmaceutical composition
quisqualate
nbqx
dopa
Prior art date
Application number
IL10045891A
Other languages
English (en)
Other versions
IL100458A0 (en
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19904041981 external-priority patent/DE4041981A1/de
Priority claimed from DE19914121483 external-priority patent/DE4121483A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL100458A0 publication Critical patent/IL100458A0/xx
Publication of IL100458A publication Critical patent/IL100458A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL10045891A 1990-12-21 1991-12-20 תכשירי רוקחות המכילים מתנגדים של קולטי קוויסקוואלייט IL100458A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19904041981 DE4041981A1 (de) 1990-12-21 1990-12-21 Neue verwendung von quisqualat-rezeptor-antagonisten
DE19914121483 DE4121483A1 (de) 1991-06-26 1991-06-26 Neue verwendung von quisqualat-rezeptor-antagonisten

Publications (2)

Publication Number Publication Date
IL100458A0 IL100458A0 (en) 1992-09-06
IL100458A true IL100458A (he) 1996-12-05

Family

ID=25899840

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10045891A IL100458A (he) 1990-12-21 1991-12-20 תכשירי רוקחות המכילים מתנגדים של קולטי קוויסקוואלייט

Country Status (12)

Country Link
US (1) US6191132B1 (he)
EP (1) EP0516795B1 (he)
JP (1) JPH05505830A (he)
AT (1) ATE180405T1 (he)
AU (1) AU655958B2 (he)
CA (1) CA2076524A1 (he)
DE (1) DE59109130D1 (he)
HU (1) HUT61467A (he)
IE (1) IE914526A1 (he)
IL (1) IL100458A (he)
PT (1) PT99864B (he)
WO (1) WO1992011012A1 (he)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313714T3 (es) * 1992-06-22 2009-03-01 The Regents Of The University Of California Antagonistas de receptores de glicina y uso de los mismos.
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
US5922715A (en) * 1997-02-18 1999-07-13 American Home Products Corporation 5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
CN1248249A (zh) * 1997-02-18 2000-03-22 美国家用产品公司 多巴胺激动剂5－氨基烷氧基－1,4－二氢喹喔啉－2,3－二酮类化合物
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
WO2004110255A2 (en) 2003-06-09 2004-12-23 Gang Zheng Antineoplastic agents targeted via glut transporters
US20090030017A1 (en) * 2005-04-08 2009-01-29 Eisai R & D Management Co., Ltd Therapeutic agent for dyskinesia
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
EP2338492A1 (en) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
IE66149B1 (en) * 1986-09-16 1995-12-13 Novo Nordisk As Quinoxaline compounds and their preparation and use
US4812458A (en) * 1986-09-16 1989-03-14 A/S Ferrosan 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
DK146787A (da) * 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
NO179551C (no) 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
DK160941C (da) 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
DK338789A (da) * 1988-07-15 1990-01-16 Schering Ag 2-substituerede ergolinylurinstofderivater og fremgangsmaade til fremstilling deraf, deres anvendelse som laegemidler samt mellemprodukter til fremstilling deraf
DK715888D0 (da) 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
US4975430A (en) * 1989-06-16 1990-12-04 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University CNQX and its analogs as therapeutics for degenerative neural diseases

Also Published As

Publication number Publication date
AU655958B2 (en) 1995-01-19
IL100458A0 (en) 1992-09-06
DE59109130D1 (de) 1999-07-01
JPH05505830A (ja) 1993-08-26
PT99864A (pt) 1992-12-31
HUT61467A (en) 1993-01-28
CA2076524A1 (en) 1992-06-21
PT99864B (pt) 1999-06-30
ATE180405T1 (de) 1999-06-15
HU9202990D0 (en) 1992-12-28
US6191132B1 (en) 2001-02-20
EP0516795B1 (de) 1999-05-26
IE914526A1 (en) 1992-07-01
EP0516795A1 (de) 1992-12-09
WO1992011012A1 (de) 1992-07-09
AU9139791A (en) 1992-07-22

Similar Documents

Publication Publication Date Title
Blanchet et al. Effects of the full dopamine Dl receptor agonist dihydrexidine in Parkinson's disease
US20100144858A1 (en) Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
US6191132B1 (en) Use of quisqualate receptor antagonists
CZ316797A3 (cs) Použití derivátů imidazo(1,2a)-pyridin-3-acetamidu pro léčbu neuropsychiatrických syndromů asociovaných s dysfunkcí neurálních okruhů bazálních ganglií
WO2007118276A1 (en) Method of treatment of age-related macular degeneration(amd)
JPH062672B2 (ja) パーキンソン疾患治療用薬剤
JP2011037877A (ja) ジスキネジーの治療
US20020048612A1 (en) GABA substrate and the use thereof for treating cognitive and emotional disorders
CZ284928B6 (cs) Použití riluzolu pro výrobu léčiva určeného k léčení Parkinsonovy choroby a Parkinsonových syndromů
HU200557B (en) Antiparkinson ergoline derivatives
Trommer et al. NMDA receptor antagonists inhibit kindling epileptogenesis and seizure expression in developing rats
WO2004039404A1 (ja) 脊柱管狭窄症治療剤
US5622965A (en) 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists
KR20220152237A (ko) 장쇄 지방산을 포함하는 안구 건강용 조성물 및 방법
Coleman Current drug therapy for Parkinson’s disease: a review
HUT64473A (en) New combinative preparations for treating parkinson-disease
JP2618375B2 (ja) 覚醒、情動、精神運動能力の機能低下による痴呆または脳機能不全のための治療薬
FR2706303A1 (fr) Utilisation de l&#39;Efaroxan et de ses dérivés pour la préparation d&#39;un médicament destiné au traitement de la maladie de Parkinson.
KR102527378B1 (ko) 2&#39;-fl을 함유하는 도파민 감소로 말미암아 발생하는 질환의 개선, 예방 또는 치료용 조성물
EP2709608A1 (en) Method of treating postural reflex abnormality caused by parkinson&#39;s disease
JP5127092B2 (ja) 小脳機能障害を予防および治療するための２−アミノ−６−トリフルオロメトキシ−ベンゾチアゾールの使用
FR2755013A1 (fr) Nouvelle application therapeutique des antagonistes de la substance p
DE4041981A1 (de) Neue verwendung von quisqualat-rezeptor-antagonisten
DE4121483A1 (de) Neue verwendung von quisqualat-rezeptor-antagonisten
EP0609630A1 (en) Use of inhibitors of ornithine aminotransferase for the manufacture of a medicament for the treatment of Alzheimer&#39;s disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees